Skip to main content
An official website of the United States government
Español
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Enhertu

(en-HER-too)
A drug used to treat adults with certain types of HER2-positive or HER2-low breast cancer, HER2-positive stomach cancer, gastroesophageal junction cancer, or other solid tumor, or non-small cell lung cancer that has a certain mutation in the HER2 gene. It is also being studied in the treatment of other types of cancer. Enhertu contains a monoclonal antibody called trastuzumab that binds to a protein called HER2, which is found on some cancer cells. It also contains an anticancer drug called deruxtecan, which may help kill cancer cells. Enhertu is a type of antibody-drug conjugate. Also called fam-trastuzumab deruxtecan and trastuzumab deruxtecan.
More Information
Search NCI's Dictionary of Cancer Terms